JP5032990B2 - 結晶性形態のビフェニル化合物 - Google Patents

結晶性形態のビフェニル化合物 Download PDF

Info

Publication number
JP5032990B2
JP5032990B2 JP2007527919A JP2007527919A JP5032990B2 JP 5032990 B2 JP5032990 B2 JP 5032990B2 JP 2007527919 A JP2007527919 A JP 2007527919A JP 2007527919 A JP2007527919 A JP 2007527919A JP 5032990 B2 JP5032990 B2 JP 5032990B2
Authority
JP
Japan
Prior art keywords
hydroxy
methyl
ethyl
ester
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007527919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513358A (ja
JP2008513358A5 (enExample
Inventor
ロバート エス． チャオ，
ミロスラフ ラプタ，
ピエール−ジャン コルソン，
Original Assignee
セラヴァンス， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス， インコーポレーテッド filed Critical セラヴァンス， インコーポレーテッド
Publication of JP2008513358A publication Critical patent/JP2008513358A/ja
Publication of JP2008513358A5 publication Critical patent/JP2008513358A5/ja
Application granted granted Critical
Publication of JP5032990B2 publication Critical patent/JP5032990B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007527919A 2004-08-16 2005-08-15 結晶性形態のビフェニル化合物 Expired - Fee Related JP5032990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60180504P 2004-08-16 2004-08-16
US60/601,805 2004-08-16
PCT/US2005/029013 WO2006023454A1 (en) 2004-08-16 2005-08-15 Crystalline form of a biphenyl compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012065767A Division JP2012121929A (ja) 2004-08-16 2012-03-22 結晶性形態のビフェニル化合物

Publications (3)

Publication Number Publication Date
JP2008513358A JP2008513358A (ja) 2008-05-01
JP2008513358A5 JP2008513358A5 (enExample) 2008-09-18
JP5032990B2 true JP5032990B2 (ja) 2012-09-26

Family

ID=35687428

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007527919A Expired - Fee Related JP5032990B2 (ja) 2004-08-16 2005-08-15 結晶性形態のビフェニル化合物
JP2012065767A Withdrawn JP2012121929A (ja) 2004-08-16 2012-03-22 結晶性形態のビフェニル化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012065767A Withdrawn JP2012121929A (ja) 2004-08-16 2012-03-22 結晶性形態のビフェニル化合物

Country Status (25)

Country Link
US (4) US7521558B2 (enExample)
EP (1) EP1778672B1 (enExample)
JP (2) JP5032990B2 (enExample)
KR (1) KR101363352B1 (enExample)
CN (1) CN101006077B (enExample)
AR (1) AR051003A1 (enExample)
AU (1) AU2005277601B2 (enExample)
BR (1) BRPI0514413C1 (enExample)
CA (1) CA2575874C (enExample)
DK (1) DK1778672T3 (enExample)
ES (1) ES2400958T3 (enExample)
HR (1) HRP20130192T1 (enExample)
IL (1) IL180853A (enExample)
MA (1) MA28825B1 (enExample)
MX (1) MX2007001688A (enExample)
MY (1) MY141224A (enExample)
NO (1) NO338770B1 (enExample)
NZ (1) NZ552796A (enExample)
PL (1) PL1778672T3 (enExample)
PT (1) PT1778672E (enExample)
RU (1) RU2381223C2 (enExample)
SI (1) SI1778672T1 (enExample)
TW (1) TWI374883B (enExample)
WO (1) WO2006023454A1 (enExample)
ZA (1) ZA200701057B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
AU2007303909A1 (en) * 2006-10-04 2008-04-10 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US8519138B2 (en) * 2009-04-14 2013-08-27 Glaxo Group Limited Process for the preparation of a biphenyl-2-yl carbamic acid ester
CN102405218B (zh) 2009-04-23 2014-06-04 施万制药 具蕈毒碱受体拮抗剂和β2 肾上腺素受体激动剂活性的二酰胺化合物
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
IN2014CN02850A (enExample) * 2011-10-31 2015-07-03 Glaxosmithkline Intellectual Property Ltd
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
JP6307091B2 (ja) 2012-12-18 2018-04-04 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． β２アドレナリンアゴニスト活性およびＭ３ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TW201835041A (zh) 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
WO2022175982A1 (en) * 2021-02-19 2022-08-25 Gbr Laboratories Private Limited A process for preparing batefenterol and intermediates thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS596860B2 (ja) * 1975-05-19 1984-02-15 オオツカセイヤク カブシキガイシヤ ５−〔（２−アルキルアミノ−１−ヒドロキシ）アルキル〕カルボスチリル誘導体の製造法
TW297025B (enExample) * 1992-02-14 1997-02-01 Squibb & Sons Inc
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
AU783095B2 (en) 1999-12-07 2005-09-22 Theravance Biopharma R&D Ip, Llc Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2004356517A (ja) 2003-05-30 2004-12-16 Ebara Corp 基板洗浄装置及び基板洗浄方法
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
AU2005277601B2 (en) 2011-10-27
KR20070057832A (ko) 2007-06-07
CA2575874A1 (en) 2006-03-02
US20060035931A1 (en) 2006-02-16
BRPI0514413A (pt) 2008-06-10
HRP20130192T1 (hr) 2013-04-30
NO20071307L (no) 2007-04-11
BRPI0514413C1 (pt) 2021-05-25
US8754223B2 (en) 2014-06-17
MY141224A (en) 2010-03-31
RU2381223C2 (ru) 2010-02-10
AR051003A1 (es) 2006-12-13
US8101766B2 (en) 2012-01-24
JP2008513358A (ja) 2008-05-01
IL180853A0 (en) 2007-07-04
SI1778672T1 (sl) 2013-04-30
BRPI0514413B1 (pt) 2019-04-16
US7521558B2 (en) 2009-04-21
NO338770B1 (no) 2016-10-17
DK1778672T3 (da) 2013-03-25
EP1778672B1 (en) 2012-12-19
US20130289281A1 (en) 2013-10-31
CA2575874C (en) 2012-10-09
WO2006023454A1 (en) 2006-03-02
AU2005277601A1 (en) 2006-03-02
PT1778672E (pt) 2013-02-25
CN101006077B (zh) 2012-04-25
US8476299B2 (en) 2013-07-02
JP2012121929A (ja) 2012-06-28
KR101363352B1 (ko) 2014-02-14
NZ552796A (en) 2010-09-30
US20090221638A1 (en) 2009-09-03
HK1106227A1 (en) 2008-03-07
MA28825B1 (fr) 2007-08-01
TWI374883B (en) 2012-10-21
US20120283289A1 (en) 2012-11-08
CN101006077A (zh) 2007-07-25
MX2007001688A (es) 2007-04-23
TW200613296A (en) 2006-05-01
PL1778672T3 (pl) 2013-05-31
ZA200701057B (en) 2008-08-27
RU2007109598A (ru) 2008-09-27
IL180853A (en) 2014-03-31
ES2400958T3 (es) 2013-04-15
EP1778672A1 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
JP5032990B2 (ja) 結晶性形態のビフェニル化合物
US7320990B2 (en) Crystalline form of a biphenyl compound
JP4555283B2 (ja) β２アドレナリン作動性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するビフェニル誘導体
JP4837653B2 (ja) ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2008532921A (ja) ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2007528416A (ja) ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2007528412A (ja) ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
JP2007528408A (ja) ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2007528415A (ja) ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2008533026A (ja) ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
JP2007528410A (ja) ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2007528413A (ja) ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2008533028A (ja) ムスカリン性受容体アンタゴニストとして有用なビフェニル化合物
JP2007528418A (ja) ムスカリンレセプターアンタゴニストとしての有用なジフェニルメチル化合物
HK1106227B (en) Crystalline form of a biphenyl compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120620

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120629

R150 Certificate of patent or registration of utility model

Ref document number: 5032990

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150706

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees